Pepgen reports fourth quarter and year-end 2024 financial results and recent corporate highlights

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended december 31, 2024, and recent corporate highlights. “today, we reported initial results from freedom-dm1, which showed robust splicing correction in patients with dm1 following a single dos.
PEPG Ratings Summary
PEPG Quant Ranking